Marketing: Page 3


  • An outside view of an Amgen building.
    Image attribution tooltip
    Amgen Inc.

    Amgen expects rising sales through 2030, but Wall Street still has doubts

    Facing falling sales of top-seller Enbrel, the biotech tried to shore up confidence in its ability to grow new products, like the cancer drug Lumakras.

    By Kristin Jensen • Feb. 9, 2022
  • Biogen
    Image attribution tooltip
    Permission granted by Biogen

    Biogen buys into fast-advancing Roche cancer drug

    The biotech will pay $30 million to opt into rights for mosunetuzumab, a bispecific antibody that Roche has developed for non-Hodgkin's lymphoma.

    By Feb. 1, 2022
  • A photo of Biogen's Alzheimer's drug Aduhelm
    Image attribution tooltip
    Permission granted by Biogen

    Medicare faces blowback over plan to limit coverage of Biogen's Alzheimer's drug

    Biogen, along with allies in industry, plans to pressure Medicare to water down its policy, which limits coverage of Aduhelm and drugs like it to clinical trials.

    By , Jan. 14, 2022
  • A photo of a Biogen building
    Image attribution tooltip
    Permission granted by Biogen

    Medicare proposes to limit coverage of Biogen Alzheimer's drug

    The program will only cover Aduhelm, which the FDA controversially approved last June, for patients enrolled in rigorous clinical trials, likely forestalling broader adoption of the treatment.

    By , Updated Jan. 11, 2022
  • Image attribution tooltip
    Novartis

    Novartis wins FDA approval for new heart drug, but faces uphill sales battle

    Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations. But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness.

    By Dec. 22, 2021
  • A photo of Biogen's Alzheimer's drug Aduhelm
    Image attribution tooltip
    Permission granted by Biogen
    Biogen's new Alzheimer's drug

    After intense pushback, Biogen to cut price of Alzheimer's drug

    Effective Jan. 1, the average list price for Aduhelm will drop about 50% to just over $28,000 a year. It's a move the company hopes will appease insurers and lower out-of-pocket costs for patients.

    By Dec. 20, 2021
  • Biogen
    Image attribution tooltip
    Permission granted by Biogen
    Biogen's new Alzheimer's drug

    European regulators say no to Aduhelm, but Biogen is pushing back

    The company plans to ask the European Medicines Agency to reexamine its conclusion that "the benefits of Aduhelm do not outweigh its risks."

    By Dec. 17, 2021
  • Johnson & Johnson vaccine vials against the COVID-19 coronavirus are seen at the Klerksdorp Hospital as South Africa proceeds with its inoculation campaign on February 18, 2021
    Image attribution tooltip
    Phill Magakoe via Getty Images

    J&J's coronavirus vaccine faces new US limits

    Days after the FDA strengthened safety warnings for J&J's shot, a CDC panel recommended Pfizer's and Moderna's vaccines be "preferred."

    By Updated Dec. 17, 2021
  • Image attribution tooltip
    Fotolia

    Humana, Centene sue drugmakers, alleging anticompetitive practices on HIV drugs

    The insurers filed suit against Gilead, J&J, Bristol Myers Squibb and Teva, claiming the drugmakers conspired to protect lucrative HIV drugs from competition.

    By Rebecca Pifer • Dec. 14, 2021
  • The outside of an AbbVie building, with the company's logo displayed.
    Image attribution tooltip
    AbbVie

    AbbVie's blockbuster weighed down by safety concerns for a similar Pfizer drug

    Like Pfizer's Xeljanz, the label for AbbVie's Rinvoq has been updated to warn about risks of death and major cardiovascular events like stroke.

    By Dec. 6, 2021
  • Image attribution tooltip

    Stockbakery/Shutterstock.com

    Sponsored by Veeva Crossix

    Audience targeting in a changing digital landscape

    How will your digital advertising strategy evolve in a future without cookies?

    Dec. 6, 2021
  • A photo of Biogen's Alzheimer's drug Aduhelm
    Image attribution tooltip
    Permission granted by Biogen
    Biogen's new Alzheimer's drug

    Anticipating Aduhelm's costs, Medicare plans big jump in premiums

    While CMS is still weighing whether to authorize wide coverage of Biogen's pricey Alzheimer's drug, administrators are planning to build reserves in case costs skyrocket.

    By Nov. 15, 2021
  • Image attribution tooltip

    Permission for use granted by IQVIA

    Sponsored by IQVIA

    IQVIA Omnichannel Navigator: A platform for informing smarter marketing decisions

    This year, the pharmaceutical industry will spend more on its promotional activities than any year before. It’s estimated that the total U.S. promotional spend for 2021 will be around $30 billion.

    By Kathryn Grimshaw • Nov. 8, 2021
  • Image attribution tooltip

    Permission granted by IQVIA

    Sponsored by IQVIA

    Patients, payers, policy and pressure: Trends to watch in 2021

    It has become increasingly difficult to forecast and achieve net sales goals. Pressures were building long before 2020, and the COVID-19 pandemic has only accelerated and amplified the challenges.

    Nov. 1, 2021
  • Image attribution tooltip
    Jon Cherry via Getty Images

    CDC panel backs COVID-19 boosters for Moderna, J&J vaccine recipients

    Advisers' recommendations followed the FDA's clearance of additional doses for certain people vaccinated with Moderna's and J&J's shots, while also endorsing a mix-and-match approach.

    By , Shoshana Dubnow • Updated Oct. 22, 2021
  • A photo of a Biogen sign
    Image attribution tooltip
    Permission granted by Biogen
    Biogen's new Alzheimer's drug

    Biogen's Alzheimer's drug is struggling, and a turnaround might not be coming soon

    Sales of Aduhelm during the third quarter totaled only $300,000, falling well below expectations amid controversy over its approval and physician reluctance to prescribe it.

    By Oct. 20, 2021
  • Image attribution tooltip
    Getty Images

    Sage, Biogen detail plans to get their newer depression drug approved

    Following discussions with the FDA, the companies plan to submit zuranolone for approval in major depressive disorder and postpartum depression over the next roughly year and a half.

    By Oct. 19, 2021
  • Boehringer wins 'interchangeable' status for Humira copy, strengthening competitive threat

    The interchangeable approval could help to boost adoption of Boehringer's biosimilar when it launches in mid-2023, a date set via settlement with AbbVie.

    By Oct. 18, 2021
  • Lilly drug cleared by FDA for wider use in breast cancer

    Verzenio now has an expanded approval for treatment of a common form of early cancer, although the label granted by FDA places some limits on use.

    By Kristin Jensen • Oct. 13, 2021
  • Biohaven's Nurtec NASCAR car
    Image attribution tooltip
    Permission granted by Biohaven Pharmaceutical

    Biohaven migraine drug sales again top Wall Street forecasts

    The neuroscience-focused biotech continues to win market share in a battle with some of the industry's largest companies.

    By Kristin Jensen • Oct. 6, 2021
  • The front of the department of health and human services building with a sign in front of the exterior building
    Image attribution tooltip
    Mark Wilson via Getty Images

    Lilly, Novartis, other pharmas could face fines for violating 340B law

    The U.S. health department asked its inspector general to review the refusals of six drugmakers to offer discounts to safety net hospitals through community pharmacy partnerships.

    By Rebecca Pifer • Sept. 24, 2021
  • Image attribution tooltip
    Kevin C. Cox via Getty Images

    CDC recommends Pfizer booster shots for many, overruling advisers on broad use

    While agency advisers voted against recommending a third Pfizer vaccine dose for frontline workers, they were overruled by CDC Director Rochelle Walensky, who officially endorsed use in that group.

    By Shoshana Dubnow , Updated Sept. 24, 2021
  • Takeda wins FDA approval for targeted lung cancer drug

    Exkivity follows Johnson & Johnson's Rybrevant on the market for treating lung tumors harboring specific mutations in the EGFR gene. Unlike J&J's drug, however, Takeda's is given orally. 

    By Kristin Jensen • Sept. 16, 2021
  • A clinical trial participant is given Pfizer and BioNTech's experimental COVID-19 vaccine at the University of Maryland School of Medicine
    Image attribution tooltip
    Permission granted by University of Maryland School of Medicine

    New data from Israel, Pfizer show potent effect from third coronavirus shot

    The much-anticipated data arrive ahead of an important FDA advisory meeting to discuss authorization of a booster dose for Pfizer's coronavirus vaccine.

    By Sept. 15, 2021
  • Image attribution tooltip

    Permission granted by IQVIA

    Sponsored by IQVIA

    Overcoming inertia: Adopting omnichannel marketing for pharma

    Pharmaceutical companies are increasingly attracted to the idea of replacing the current multichannel marketing focus with an omnichannel marketing approach. But the industry is struggling to break out of its own silos.

    By Andrew Burkus, Principal, Omnichannel Marketing, IQVIA • Sept. 13, 2021